SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing intense downward pressure driven by a combination of broader market volatility, sector-wide rotation out of mega-cap tech, and investor anxiety following recent legal rulings regarding addictive product design. While some in the community are panic-selling and calling for further declines, many retail participants are debating whether these developments represent a long-term structural threat to the companys business model or a temporary overreaction providing a lucrative buying opportunity.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is facing intense volatility as market participants react to escalating geopolitical tensions and erratic messaging surrounding potential military actions in the Middle East. The community is actively debating the stock's stability amidst heavy skepticism regarding official communications, with many users focusing on the broader impact of administration policies on both their portfolios and the global economy.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is drawing significant attention after reporting preliminary Q1 financial results that exceeded guidance and revealing plans to wind down its non-core ironSource Ads Network to focus on higher-growth segments like Unity Vector. While some investors are expressing optimism about a potential bottom and long-term recovery fueled by AI integration and strategic cost-cutting, others remain wary of the stock's persistent volatility and the broader sector-wide headwinds affecting software valuations.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently experiencing significant volatility as investors weigh the company's ambitious autonomous and robotics growth narrative against mounting regulatory scrutiny over its FSD technology and broader macroeconomic pressure from regional conflict. Market participants are actively debating the potential impact of a possible SpaceX IPO and the reliability of Tesla's future product promises, leading to intense speculation among both retail and institutional traders regarding the stock's near-term direction.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is trending as investors digest positive topline results from the GLOW2 Phase 3 study, which met primary and secondary endpoints for treating diabetic retinopathy. The community is actively debating the company's regulatory path and potential for a short squeeze, while highlighting the significance of the clinical data in de-risking the pipeline and reigniting interest in its long-acting therapeutic platform.

Greenland Energy Co.

Greenland Energy Company (GLND) is trending following its recent business combination and the appointment of former TD Ameritrade CEO Joe Moglia as an executive advisor. The community is actively discussing the company's potential to unlock massive oil reserves in the Jameson Land Basin, with many traders drawing parallels to other energy sector plays and highlighting the involvement of major industry partners like Halliburton.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is trending due to positive interim Phase 1 data for its obesity candidate WVE-007, which demonstrated promising visceral fat reduction and lean muscle preservation. The community is actively debating the trial's methodology regarding patient BMI while weighing the stock's significant volatility against a growing consensus of bullish analyst sentiment and potential long-term value in the obesity treatment space.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding is experiencing intense volatility and downward pressure as investors rotate out of consumer apparel and footwear stocks amid tariff concerns and shifting growth expectations. Despite the sell-off, the community remains deeply divided, with many bulls highlighting robust brand momentum, consistent earnings beats, and successful market share gains against industry giants as reasons to accumulate on the dip.

Akamai Technologies, Inc. engages in the provision of cloud services for delivering, optimizing, and securing content and business applications over the Internet. Its products include security, web performance, media delivery, and network operator. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

Akamai is currently trending as investors focus on the company's strategic pivot toward edge computing and AI-driven cybersecurity infrastructure. Community discussion is heavily centered on the company's partnership with NVIDIA and its potential to capture long-term structural opportunities in AI inferencing, despite recent volatility driven by earnings guidance and broader sector-wide macro pressures.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is seeing increased investor attention as the company enters a strategic ad partnership with Pacvue, aimed at expanding its enterprise-scale advertising capabilities. While the community remains divided over management's stock sales and the platform's long-term monetization potential, many traders are closely watching how the stock recovers from recent volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.

Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8% - What's Next?

Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 4.8% - What's Next...

Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading Volume - Here's What Happened

Xilio Therapeutics (NASDAQ:XLO) Sees Strong Trading Volume - Here's Why...

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Xilio Therapeutics ended nearly 8% higher on Tuesday after the company reported positive early trial results for its cancer drug XTX301, began dosing patients in Phase 2, and secured a $17.5 million milestone payment from Gilead Sciences.Xilio said Phase 1 data for XTX301, a tumor-activated IL-12 therapy, showed anti-tumor activity in patients with advanced solid tumors, including two partial responses, while most side effects were mild or moderate.&nbsp;The treatment also sustained interferon gamma signaling across cycles, supporting the company’s approach of reprogramming “cold” tumors into inflamed “hot” ones.Based on the findings, Xilio selected a recommended Phase 2 dose and schedule and has begun treating patients in the Phase 2 portion of its ongoing Phase 1/2 trial in the U.S, which will enroll about 40 participants.&nbsp;Enrollment in Phase 1A has been completed, and Phase 1B expansion is still underway.The milestone payment from Gilead, tied to the start of Phase 2, extends Xilio’s cash runway into the first quarter of 2027. As of June 30, the company held $121.6 million in cash and equivalents and expects to receive the Gilead payment in the fourth quarter of 2025.Under their March 2024 global license agreement, Gilead may take over development and commercialization of XTX301 after reviewing clinical data, with an option fee of $75 million.&nbsp;Xilio could receive up to $500 million in additional development, regulatory and sales milestones, plus tiered royalties ranging from high single digits to mid-teens on global net sales.On Stocktwits, retail sentiment for Xilio was ‘bullish’ amid a 2,333% surge in 24-hour message volume.One user said that the stock had “solid news” but needed more trading volume to push through the $0.80 level.<stembedurl>https://stocktwits.com/MrTicker/message/627979369</stembedurl>Another user predicted the shares would climb quickly, noting it was “super hard to get shares.”&nbsp;They highlighted that Xilio held about $140 million in cash against a roughly $38 million market cap, arguing the market had assigned little to no value to its partnerships, assets, or even its cash balance, and suggesting a reprice was likely.<stembedurl>https://stocktwits.com/SteadyTrade55/message/627979366</stembedurl><a href="https://stocktwits.com/symbol/XLO">Xilio’s stock</a> has declined 21.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Xilio’s stock has declined 21.5% so far in 2025. (Photo credit: Getty Images)

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

The company has begun dosing patients in Phase 2 of its trial for XTX301, a tumor-activated IL-12 therapy that showed two partial responses in early testing and was generally well tolerated.

Equity

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of -100.00% and -10.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Xilio Therapeutics Inc

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

XLO
Xilio Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XLO News

XLOXilio Therapeutics Inc